GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

IXICO IXI.L · GBp

Health Care · LSE · 🇬🇧 United Kingdom

Compare

13.00p

0.00%

Close of 9 Nov 2026, in pence

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About IXICO

Its shares trade on LSE under the ticker IXI.L. It has been listed since 4 September 2013. In the fiscal year to 30 September 2025, it reported revenue of £6.5m and a net loss of £1.7m. At that date it held total assets of £13.8m and shareholders' equity of £11.7m.

IXICO Plc engages in the provision of technology-enabled specialty services to the global biopharmaceutical industry. The firm's brain health focus includes Alzheimer's disease, Huntington's disease, Parkinson's disease, behavioral health and adolescent mental health. The company is a provider of clinical trials services to pharmaceutical companies. Its products include Assessa, mehealth, MyBrainBook and TrialTracker. Assessa is a decision-support tool for healthcare professionals looking to diagnose dementia and detect the underlying causes. mehealth is an online software for clinicians at the point-of-care to support decision making and improve the monitoring and treatment of patients. MyBrainBook is a digital platform to improve the quality of life and service delivery for people living with dementia and their supporters. TrialTracker is a Web-based system that allows users to track their imaging-based research study or clinical trial in real time. The company is also collaborating with partners to develop companion digital health products.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Life Sciences Tools & Services
Listed since
4 Sept 2013
Employees
68
Website
ixico.com ↗

Leadership

Pay as last reported

  • Mr. Mark WarneNon-Executive Independent Chairman of the Board£47,000
  • Mr. Bram GoordenChief Executive Officer, Executive Director, since 2024£44,000
  • Mr. Grant NashChief Financial Officer, Executive Director, Company Secretary, since 2019£221,000
  • Dr. Dipti AminNon-Executive Independent Director£31,000
  • Ms. Katherine RogersSenior Non-Executive Independent Director£31,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.